ga

** skip to content **

Mes fichiers [0]

Ce sont les fichiers que vous avez ajouté à votre collection.

  • ** cart_no_document_in_cart **

ACMTS » Rechercher dans tous les produits » Programme commun d'évaluation des médicaments » Le Point sur le PCEM » Le point sur le PCEM - numéro 8

Le point sur le PCEM - numéro 8

Submission Status

The CDR Directorate has received two submissions:

  • Combigan® (brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution, Allergan Canada Inc)
  • Reyataz™ (atazanavir, Bristol-Myers Squibb Canada).

Submission Status Reports are available on the CCOHTA web site. These will be updated weekly. A Submission Status Report tracks the progress of a submission from receipt by the CDR Directorate through to the release of the final recommendation and reasons for recommendation by the Canadian Expert Drug Advisory Committee (CEDAC).

The Submission Status Report provides manufacturers, government representatives and public stakeholders with information about the progress of drug submissions through the CDR process. Data will be used to assist in the evaluation of the CDR process after one full year of operation.

Christmas and New Year’s Holiday Schedule

The CDR Directorate office is closed for the holiday season from December 25, 2003 to January 2, 2004, inclusive. The CDR Directorate reminds manufacturers that the timeframes for the review process are based on business days. Submissions will not be processed while the office is closed.

Communications Officer Leaving CDR Directorate

Stefania (Allevato) Moffatt joined the CDR Directorate in July 2003 as Communications Officer. Stefania is leaving in December. The CDR Directorate wishes Stefania all the best as she takes on new challenges in her career.